title: Indirect hyperbilirubinemia with indinavir.
abstract: Indinavir is a protease inhibitor used in the treatment of HIV infected individuals and as post-exposure prophylaxis. Indinavir is associated with various adverse effects including gastrointestinal, a lipodystrophy syndrome and nephrolithiasis. We describe indirect hyperbilirubinemia as an adverse effect of indinavir in a person on post-exposure prophylaxis (PEP).
authors.affiliation: Department of Medicine, TN Medical College and BYL Nair Charitable Hospital, Mumbai.
authors.forename: P
authors.initials: P
authors.lastname: Satija
authors.forename: Falguni
authors.initials: F
authors.lastname: Parikh
authors.forename: V
authors.initials: V
authors.lastname: Aggarwal
authors.forename: B
authors.initials: B
authors.lastname: Sharma
authors.forename: Avi
authors.initials: A
authors.lastname: Hakim
authors.forename: J V
authors.initials: JV
authors.lastname: Pai-Dhungat
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced* / Q000503:physiopathology; D007194:India; D019469:Indinavir / Q000009:adverse effects* / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D008111:Liver Function Tests; D016602:Needlestick Injuries / Q000821:virology*; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D017320:HIV Protease Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir